Effect of Relaxin Expressing Adenovirus on Scar Remodeling: A Preliminary Study by 김용욱 et al.
Archives of Craniofacial Surgery
Copyright © 2017 The Korean Cleft Palate-Craniofacial Association
  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/







Arch Craniofac Surg Vol.18  No.1, 9-15
https://doi.org/10.7181/acfs.2017.18.1.9
INTRODUCTION
Scars occurring as the result of wound healing are able to elicit 
functional disability due to secondary scar contracture in addi-
tion to aesthetic and structural disorders. In cases of burn scars, 
scar contracture, in particular, can generate severe functional 
problems in the facial or joint region [1]. Moreover, pathologic 
scars, such as keloids and hypertrophic scars, enlarge drastically, 
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Conclusion: Relaxin-expressing adenoviruses improved the surface area, color, and pli-
ability of scars. The mechanism of therapeutic effects on scar formation should be further 
investigated.
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resulting in an intractable disease, as it may relapse postoperative-
ly. Fundamental treatments for scars have not yet been developed. 
In addition to wound healing, scar development remains an im-
portant research area in medicine. Although a large number of 
studies have investigated the mechanism of scar development to 
both minimize and alter scar formation, treatments for scars have 
not yet been fully realized [2].
Relaxin is a 6-kDa polypeptide hormone belonging to the in-
sulin-like growth factor (IGF) family; it is primarily produced in 
the corpus luteum and endometrium [3]. Recent studies revealed 
that relaxin exhibits biological activation in reproductive tissues 
and other organs [4-6]. Relaxin has anti-fibrotic effects that reduce 
inflammation and collagen synthesis. Relaxin is also known to 
reduce the activation of transforming growth factor β1 (TGF-β1), 
which plays an important role in scar formation. Through this 
process, the differentiation of fibroblasts into myofibroblasts is 
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anticipated to slow. This anti-fibrotic effect of relaxin is thought to 
reduce scar formation. In addition, the effects of relaxin on mast 
cells, which play crucial roles in scar formation, must be verified 
[7-9].
To overcome the very short biological half-life of relaxin (<4 
minutes), adenoviruses expressing the relaxin gene were used as 
vectors. Gene therapy using adenoviruses has been primarily in-
vestigated for anti-tumor effects [10]. Instead of using the E1 gene, 
which is essential for adenovirus duplication, the relaxin gene was 
inserted into a non-duplicable adenovirus to prolong its effects by 
amplifying its expression both in and around adenovirus-infected 
cells. Since non-duplicable adenoviruses show anti-tumor effects 
in localized areas, they are considered to be suitable for the treat-
ment of scars and other fibrotic diseases [10,11].
We aim to verify the effects of relaxin on scar remodeling by 
injecting relaxin-expressing adenoviruses in a pig scar model.
METHODS
Scar formation
The scar model was created using three Yorkshire pigs (4 months 
of age, 40 kg). Anesthesia was induced in each pig via an intra-
muscular injection of Zoletil (5 mg/kg, Virbac, Carros, France) 
and Rompun (2 mg/kg, Bayer, Seoul, Korea); all hairs were then 
removed from both the back and belly of each pig. Inhalation an-
esthesia was induced using isoflurane (IsoFlo, Abbott Laborato-
ries, Abbott Park, IL, USA). After anesthetizing the pigs, a total of 
36 full-thickness skin defects (3×3 cm2) were made on a back of 
each Yorkshire pig symmetrically, consisting of 18 wounds on 
each side of the midline. The depth of each wound was to the 
depth of the muscle fascia to mimic scar formation. The interval 
of each wound was maintained between 3–5 cm to control the in-
fluence of the wounds on the process of wound healing. Both IV 
antibiotics and wound dressings with TegaDerm (3M, St Paul, 
MN, USA) were administered postoperatively for 5 days, and then 
an open dressing was maintained. Fifty days later, scar tissues dis-
tinct from peripheral normal tissues formed (Fig. 1) [12]. 
Production of relaxin-expressing adenoviruses
Relaxin-expressing and E1- and E3-deleted adenovirus vectors were 
produced according to the conventional method [8,10,12-14]. To de-
velop an adenovirus encoding arginylglycylaspartic acid (RGD) 
consisting of the 9-amino acid sequence (CDCRGDCFC) between 
the HI-loop of the fiber knob, two complementary oligonucleotides 
encoding Arg-Gly-Asp were first synthesized and annealed to form 
a DNA duplex. This DNA duplex was designed to contain a BamHI 
overhang on the 5′ end and an MroI overhang on the 3′ end. The oli-
gonucleotide sequences were 5′-gatccTGTGACTGCCGCGGAGA-
CTGTTTCTGCt-3′ and 5′-ccggaACAATGACGGCGCCTCT-
GACAAAGACGg-3′. The annealed DNA duplex was then digested 
with NcoI and MfeI and cloned into pSK5543, generating a pSK 
(5543-RGD) adenovirus fiber shuttle vector.
The pSK (5543-RGD) shuttle vector was then linearized with 
SacI and XmnI, and the lacZ-expressing adenoviral vector pdE1/
lacZ was linearized with SpeI for homologous recombination in 
Escherichia coli BJ5183, resulting in the pdE1-RGD/lacZ adenovi-
ral vector. To construct an adenovirus expressing lacZ and RLX at 
the E1 and E3 regions, respectively, pdE1-RGD/lacZ was linear-
ized with SpeI and co-transformed into Escherichia coli BJ5183 
Fig. 1. (A) Pig scar model and scar formation. (A) A total of 36 full-
thickness skin defects (3×3 cm2) were made on the backs of Yorkshire 
pigs symmetrically, consisting of 18 wounds on each side of the mid-
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with the PvuI-digested pSP72-E3/CMV-RLX shuttle vector for 
homologous recombination, producing the pdE1-RGD/lacZ/RLX 
adenoviral vector. All adenoviruses were developed and multiplied 
in 293 cells. Viral particle numbers were calculated from measure-
ments of absorbance at 260 nm, where 1absorbency unit is equiva-
lent to 1012 viral particles per milliliter [8,10,12-14]. Virus was dilut-
ed with phosphate buffered saline (PBS)  to 5×107 PFU [15].  
Injection of adenovirus
On the 50th postoperative day, wound epithelialization and scar 
formation occurred. Anesthesia was induced in each pig by an in-
tramuscular injection of Zoletil (5 mg/kg) and Rompun (2 mg/
kg); all hairs were then removed from both the back and belly of 
each pig. Virus injection was performed using a 27-gauge needle 
and a 1-mL syringe, and adenoviruses were injected into the in-
tradermal layer of the scar regions. Scars were divided into two 
groups; 5×107 PFU relaxin-expressing adenoviruses vectors (dE1-
RGD/LacZ/RLX) were injected into the experimental group 
(RLX). The same amount of adenoviruses not containing the re-
laxin gene (dE1-RGD/LacZ) was injected into the control group 
under the same conditions.  
Evaluation
The surface area, color, and pliability of scars were compared and 
evaluated in the two groups. Evaluation was performed every 10 
days until the 50th day after virus injection. The surface areas of 
scars were compared by taking scar images using a digital camera. 
By using 1 cm2 as the standard, measured with a ruler on the image, 
the surface areas of the scars were compared and assessed using Im-
age J software (National Institutes of Health, USA). A spectropho-
tometer (CM-700D; KONICA MINOLTA, INC., Tokyo, Japan) was 
used to quantitatively analyze the color of the scars. The color of 
each scar was analyzed using melanin (the degree of scar darkness) 
and erythema (the degree of scar redness) indices [15].  Pliability was 
measured using a durometer (H1000 Mini-Dial, RexGauge Co., 
Buffalo Grove, IL,  USA). Each value was measured more than three 
times, and their average value was used for analysis. 
Statistical analysis
All test results were presented as the means± standard error of the 
mean (SEM), and the results of the quantitative analysis were sta-
tistically analyzed in the two groups using t-test. A p-value less 
than 0.05 (p<0.05) was considered statistically significant. Statisti-
cal analysis was performed using SAS software (ver. 9.1.3, SAS In-
stitute Inc., Cary, NC, USA).
RESULTS
Scar area
After virus injection, decreases were seen in the surface areas of 
scars in all groups over time. However, a more significant decrease 
in scar area was found in the RLX  group compared with the con-
trol group (Fig. 2). The sizes of the initial scar were 3.15±0.15 cm2 
and 3.12±0.11 cm2 in the RLX and control groups, respectively. 
However, the sizes were 1.70±0.10 cm2 in the control group 50 days 
after virus injection. The size was reduced to 1.37±0.05 cm2 in the 
RLX group, which was a significant decrease (p<0.05) (Fig. 3).
Scar color 
Immediately after scar formation, erythema indices representing the 
redness of the scar were 2.01±0.10 and 2.01±0.09 in the control and 
RLX groups, respectively, with no significant differences between 
the two groups. Fifty days after virus injection, erythema indices 
were 2.05±0.08 and 1.52±0.15, respectively, in the control and RLX 
groups (Fig. 4). Moreover, melanin indices indicating the degree of 
scar darkness of scar were in 0.23±0.02 and 0.23±0.03 in the control 
and RLX groups, respectively, with no significant differences be-
tween the two groups. Fifty days after virus injection, melanin indi-
ces were 0.21±0.04 and 0.08±0.02, respectively, in the control and 
RLX groups (Fig. 5). No significant differences were shown between 
the erythema and melanin indices measured immediately after scar 
formation and 50 days after injection using spectrophotometry in 
the control groups. In contrast, significant decreases were seen in the 
erythema and melanin indices in the RLX group (p<0.05).
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Scar pliability 
The pliability of the scars increased as evaluated durometry values 
decreased. Immediately after the formation of the scar, durometry 
values were 19.73±0.88 and 19.08±1.06 in the control and RLX 
groups, respectively, with no significant differences. Fifty days af-
ter injection of virus, the values decreased to 17.46±1.62 and 11.15
±1.72, respectively, in the control and RLX groups. Pliability in-
creased in all groups over time. Pliability significantly increased 
in the RLX group compared with control groups (p<0.05) (Fig. 6). 
 
DISCUSSION
Scars developing after a trauma or surgery incur a large number 
of functional problems. With improvements in one’s economic 
status, many patients want to minimize scar formation and en-
hance wound healing. For this reason, a large number of preserva-
tive treatments, including scar revision and laser therapy, have 
Fig. 2. Scar surface change. The surface area of the scars decreased in all groups and persisted for 50 days after virus injection. A greater decrease 
was observed in the RLX group. Cont., control group; RLX, relaxin group.
Fig. 3. Scar surface area. The sizes of the initial scar were 3.15±0.15 cm2 
and 3.12±0.11 cm2 in the RLX and control groups, respectively. The scar 
sizes were 1.70±0.10 cm2 in the control group 50 days after virus injection. 
The size was reduced to 1.37±0.05 cm2 in the RLX group, which was a sig-
nificant decrease (*p<0.05). RLX, relaxin group; Cont., control group.
Fig. 4. Erythema index. Immediately after scar formation, erythema 
indices were 2.01±0.10 and 2.01±0.09 in the control and RLX groups, 
respectively. Fifty days after virus injection, erythema indices were 
2.05±0.08 and 1.52±0.15, respectively, in the control and RLX groups 
(*p<0.05). RLX, relaxin group; Cont., control group.
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been applied to prevent scar formation. However, the successful 
treatment of scars has not been fully realized [16-18].
Several factors are involved in the formation of a scar. Contin-
ued inflammation in a wound increases the expression of TGF-β1, 
which leads to the accelerated differentiation of fibroblasts into 
myofibroblasts. The major cause of fibrotic scar contraction is 
considered the elevated α-SMA levels in myofibroblasts. Further-
more, TGF-β1 is believed to be involved in abnormal fibrosis by 
synthesizing extracellular matrix and infiltrating the interstitial 
tissues [18-23].
Mast cells, also involved in the process of wound healing, are 
reported to be involved in the proliferation and contraction of fi-
broblasts, and the synthesis of extracellular matrix. They are also 
thought to play a crucial role in scar formation. The amount of 
mast cells was four times higher in hypertrophic scars than in 
normal skin tissues [24-26].
Animal models are essential for advances in scar improvement. 
However, scars are rarely formed in animals, unlike in humans. 
We have created an animal scar model by making full-thickness 
skin defects on the backs of pigs that are similar to human scars 
[27-30]. In this study, we used human relaxin-expressing adenovi-
ruses in the pig scar model. Both human and porcine relaxin 
showed similar biological activity in a previous study [31]. Addi-
tionally, human relaxin was also effective in a porcine scar model 
[32].
We carried out a relaxin gene therapy study on keloids and lo-
cal ischemic flaps using relaxin-expressing adenoviruses [12-14]. 
Relaxin gene therapy on keloids was the previous stage of this 
study. Relaxin is anticipated to have positive effects on the treat-
ment and prevention of keloids by reducing the expression of col-
lagen I and III, both excessively expressed in keloids, and by de-
creasing the levels of elastin and fibronectin, which are both 
increased in keloids.
This study was performed using an in vivo experimental mod-
el by adopting a pig scar model. The aim of this study was to verify 
the anti-fibrotic effect of relaxin on scars. When relaxin-express-
ing adenoviruses were injected into pig scars, the reduction of the 
surface area of the scar was accelerated clinically and skin color 
was normalized. Moreover, the flexibility of the scar was im-
proved. 
These improvements of scars were believed to be caused by in-
hibiting TGF-β1 expression and decreasing the number of mast 
cells, which play crucial roles in scar formation. The inhibition of 
TGF-β1 by relaxin in scar tissues was reported previously 
[8,12,13,19]. Relaxin was shown to decrease mast cell numbers in a 
swine model of acute myocardial infarction [33,34]. The inhibi-
tion of TGF-β1 and the decrease in mast cell number by relaxin 
may prevent the conversion of fibroblasts into myofibroblasts 
during the scar remodeling process. 
This study has several limitations as a preliminary study. First, 
Fig. 5. Melanin index. Melanin indices were in 0.23±0.02 and 0.23±0.03 
in the control and RLX groups, respectively, with no significant differ-
ences between the two groups. Fifty days after virus injection, melanin 
indices were 0.21±0.04 and 0.08±0.02, respectively, in the control and 
RLX groups (*p<0.05). RLX, relaxin group; Cont., control group.
Fig. 6. Scar Pliability. The pliability of the scars increased as evaluat-
ed durometry values decreased. Immediately after the formation of 
the scar, durometry values were 19.73±0.88 and 19.08±1.06 in the 
control and RLX groups, respectively, with no significant differences. 
Fifty days after injection of virus, the values decreased to 17.46±1.62 
and 11.15±1.72, respectively, in the control and RLX groups 
(*p<0.05). RLX, relaxin group; Cont., control group.
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inherent to an animal study is the question of whether the same 
effect would be observed in human. Second, we obtained the re-
sults for 50 days after viral injection. The duration of 50 days 
would be short to evaluate the entire process of scar maturation 
and remodeling. Third, all results in this study were obtained 
through the gross findings as surface area, color and pliability of 
scars. Further studies including histological study are required to 
find the definite correlation with relaxin and scar remodeling. 
Additionally, the investigation for the mechanism of relaxin in 
scar remodeling would be useful.
REFERENCES
1. Lorenz HP. Wound healing: Repair biology and wound and scar treat-
ment. In: Mathes SJ, editor. Mathes Plastic surgery. 2nd ed. Philadel-
phia: Saunders; 2006. p. 209-35.
2. Desmouliere A, Darby IA, Gabbiani G. Normal and pathologic soft 
tissue remodeling: role of the myofibroblast, with special emphasis on 
liver and kidney fibrosis. Lab Invest 2003;83:1689-707.
3. Samuel CS, Hewitson TD, Unemori EN, Tang ML. Drugs of the fu-
ture: the hormone relaxin. Cell Mol Life Sci 2007;64:1539-57.
4. Sherwood OD. Relaxin’s physiological roles and other diverse actions. 
Endocr Rev 2004;25:205-34.
5. Samuel CS, Hewitson TD. Relaxin in cardiovascular and renal dis-
ease. Kidney Int 2006;69:1498-502.
6. Dschietzig T, Bartsch C, Baumann G, Stangl K. Relaxin-a pleiotropic 
hormone and its emerging role for experimental and clinical thera-
peutics. Pharmacol Ther 2006;112:38-56.
7.  Unemori EN, Erikson ME, Rocco SE, Sutherland KM, Parsell DA, 
Mak J, et al. Relaxin stimulates expression of vascular endothelial 
growth factor in normal human endometrial cells in vitro and is asso-
ciated with menometrorrhagia in women. Hum Reprod 1999;14:800-
6.
8. Kim JH, Lee YS, Kim H, Huang JH, Yoon AR, Yun CO. Relaxin ex-
pression from tumor-targeting adenoviruses and its intratumoral 
spread, apoptosis induction, and efficacy. J Natl Cancer Inst 
2006;98:1482-93.
9. Unemori EN, Lewis M, Constant J, Arnold G, Grove BH, Normand J, 
et al. Relaxin induces vascular endothelial growth factor expression 
and angiogenesis selectively at wound sites. Wound Repair Regen 
2000;8:361-70.
10. Kim J, Cho JY, Kim JH, Jung KC, Yun CO. Evaluation of E1B gene-at-
tenuated replicating adenoviruses for cancer gene therapy. Cancer 
Gene Ther 2002;9:725-36.
11. Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A, Mehtali M. 
Efficient generation of recombinant adenovirus vectors by homolo-
gous recombination in Escherichia coli. J Virol 1996;70:4805-10.
12. Lee WJ, Kim YO, Choi IK, Rah DK, Yun CO. Adenovirus-relaxin 
gene therapy for keloids: implication for reversing pathological fibro-
sis. Br J Dermatol 2011;165:673-7.
13. Lee WJ, Choi IK, Lee JH, Lee JS, Kim YO, Rah DK, et al. Relaxin-ex-
pressing adenovirus decreases collagen synthesis and up-regulates 
matrix metalloproteinase expression in keloid fibroblasts: in vitro ex-
periments. Plast Reconstr Surg 2012;130:407e-417e.
14. Lee WJ, Yun CO, Yun IS, Kim YO, Choi IK, Yun TJ, et al. Augmenta-
tion of rat skin flap viability by relaxin-expressing adenovirus. Wound 
Repair Regen 2011;19:709-17.
15. Yun IS, Lee WJ, Rah DK, Kim YO, Park BY. Skin color analysis using a 
spectrophotometer in Asians. Skin Res Technol 2010;16:311-5.
16. Park BY, Shin IS, Yun IS. Dovetail scar revision. Dermatol Surg 
2012;38:1716-21.
17. Kim SG, Kim EY, Kim YJ, Lee SI. The efficacy and safety of ablative 
fractional resurfacing using a 2,940-Nm Er:YAG laser for traumatic 
scars in the early posttraumatic period. Arch Plast Surg 2012;39:232-7.
18. Greenhalgh DG. Consequences of excessive scar formation: dealing 
with the problem and aiming for the future. Wound Repair Regen 
2007;15 Suppl 1:S2-5.
19. Shah M, Foreman DM, Ferguson MW. Neutralising antibody to 
TGF-beta 1,2 reduces cutaneous scarring in adult rodents. J Cell Sci 
1994;107(Pt 5):1137-57.
20. Wilgus TA, Vodovotz Y, Vittadini E, Clubbs EA, Oberyszyn TM. Re-
duction of scar formation in full-thickness wounds with topical cele-
coxib treatment. Wound Repair Regen 2003;11:25-34.
21. Liu W, Chua C, Wu X, Wang D, Ying D, Cui L, et al. Inhibiting scar 
formation in rat wounds by adenovirus-mediated overexpression of 
truncated TGF-beta receptor II. Plast Reconstr Surg 2005;115:860-70.
22. Gallant CL, Olson ME, Hart DA. Molecular, histologic, and gross 
phenotype of skin wound healing in red Duroc pigs reveals an abnor-
mal healing phenotype of hypercontracted, hyperpigmented scarring. 
Wound Repair Regen 2004;12:305-19.
23. Margulis A, Nocka KH, Wood NL, Wolf SF, Goldman SJ, Kasaian 
MT. MMP dependence of fibroblast contraction and collagen pro-
duction induced by human mast cell activation in a three-dimension-
al collagen lattice. Am J Physiol Lung Cell Mol Physiol 2009;296:L236-
47.
24. Kitamura Y, Oboki K, Ito A. Molecular mechanisms of mast cell de-
velopment. Immunol Allergy Clin North Am 2006;26:387-405.
25. Sur R, Cavender D, Malaviya R. Different approaches to study mast 
cell functions. Int Immunopharmacol 2007;7:555-67.
26. Gilfillan AM, Rivera J. The tyrosine kinase network regulating mast 
cell activation. Immunol Rev 2009;228:149-69.
27. Yun IS, Jeon YR, Lee WJ, Lee JW, Rah DK, Tark KC, et al. Effect of hu-
man adipose derived stem cells on scar formation and remodeling in a 
pig model: a pilot study. Dermatol Surg 2012;38:1678-88.
28. Corr DT, Gallant-Behm CL, Shrive NG, Hart DA. Biomechanical be-
havior of scar tissue and uninjured skin in a porcine model. Wound 
Repair Regen 2009;17:250-9.
29. Wang XQ, Kravchuk O, Liu PY, Kempf M, Boogaard CV, Lau P, et al. 
15www.e-acfs.org
Bok Ki Jung et al.         Effect of relaxin on scar remodeling
The evaluation of a clinical scar scale for porcine burn scars. Burns 
2009;35:538-46.
30. Wang XQ, Liu PY, Kempf M, Cuttle L, Chang AH, Wong M, et al. 
Burn healing is dependent on burn site: a quantitative analysis from a 
porcine burn model. Burns 2009;35:264-9.
31. Zhao S, Lee HY, Sherwood OD. Porcine and human relaxin bioactivi-
ty: bioactivities of porcine relaxin and human relaxin do not differ in 
mice and rats. Ann N Y Acad Sci 2005;1041:126-31.
32. Perna AM, Masini E, Nistri S, Bani Sacchi T, Bigazzi M, Bani D. Hu-
man recombinant relaxin reduces heart injury and improves ventric-
ular performance in a swine model of acute myocardial infarction. 
Ann N Y Acad Sci 2005;1041:431-3.
33. Nistri S, Cinci L, Perna AM, Masini E, Mastroianni R, Bani D. Relaxin 
induces mast cell inhibition and reduces ventricular arrhythmias in a 
swine model of acute myocardial infarction. Pharmacol Res 
2008;57:43-8.
34. Nistri S, Cinci L, Perna AM, Masini E, Bani D. Mast cell inhibition 
and reduced ventricular arrhythmias in a swine model of acute myo-
cardial infarction upon therapeutic administration of relaxin. In-
flamm Res 2008;57 Suppl 1:S7-8.
